NEWTON, Mass. — June 6, 2007 — Clinical Data, Inc. (NASDAQ: CLDA) announced today that its Cogenics division has successfully launched the 454 Genome Sequencer FLX system (the "454 FLX system") at its facility in Meylan, France, some eight weeks after the signing of the co-marketing
agreement with Roche Diagnostics Inc., to offer "next generation" sequencing services. The system enhances Cogenics’ portfolio of services by providing whole genome sequencing, Expressed Sequence Tag sequencing, identification of small RNAs, transcriptome analysis, and metagenomics on the new platform."Our team is enthusiastic about the level of customer interest in the 454 FLX system and pleased to be able to meet our customers’ growing needs by providing complete solutions for low-cost and high-efficiency sequencing programs," stated Robert Bondaryk, Ph.D., Senior Vice President and General Manager of Cogenics. "We have already attracted new customers for the first projects on the platform and we have a strong pipeline of current and new customer interest in 454 FLX sequencing as a companion to traditional automated Sanger sequencing."
"I am truly excited about the speed and professionalism with which our team installed the 454 technology. This represents another example of Cogenics’ strong technical abilities and commitment to leveraging proven advances in technology and quality for its clients," stated Drew Fromkin, Clinical Data’s President and CEO. "We feel that the platform’s ability to deliver value to our clients will translate into rapid, healthy returns for Cogenics."
For more information about Cogenics’ offering of the 454 FLX system, as well as its other genomic resources and services, please contact Laure Turner, Product Manager for Sequencing, at +1-314-303-9147, or Claire Vigneron, Cogenics’ European Marketing Manager, at +33 (0)4 56 38 11 03. For more information about Clinical Data, visit the company’s website at www.clda.com.
About Cogenics (www.cogenics.com)
Cogenics offers more than 18 years of experience as a trusted provider of the broadest range of pharmacogenomics and molecular biology services available globally. Cogenics provides integrated services for nucleic acid extraction, genotyping, sequencing, QPCR, and gene expression, as well as serving as a biorepository, for both research and regulated environments: GLP, cGMP and CLIA. Cogenics combines operations from the acquisitions of Genaissance Pharmaceuticals, Lark Technologies (US & UK), Icoria, and Genome Express (France). Its customers include some of the world’s most respected pharmaceutical and biotechnology companies, agencies of the US National Institutes of Health, leading government and academic researchers in the international life science community, and major agricultural companies and agencies.
About Clinical Data, Inc. (www.clda.com)
Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, from targeted science to better healthcare. Its Cogenics division provides molecular biology and pharmacogenomics services to pharmaceutical and biotech companies and academics institutions in both research and regulated environments. Its PGxHealth division focuses on genetic test and biomarker development to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Vital Diagnostics division offers in vitro diagnostics solutions for the clinical laboratory. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists, and health plans worldwide.
Source: Cogenics
